Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

AstraZeneca

34 clinical trials · 34 recruiting · INDUSTRY

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by AstraZeneca

RECRUITINGPhase 3NCT06097728

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the...

Sponsor: AstraZenecaEnrolling: 82520 locations
Unresectable Pleural Mesothelioma
RECRUITINGPhase 2NCT06792695

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Sponsor: AstraZenecaEnrolling: 12020 locations
Metastatic Colorectal Cancer
RECRUITINGPhase 2NCT06219941

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer...

Sponsor: AstraZenecaEnrolling: 22420 locations
Gastric CancerGastroesophageal Junction CancerBiliary Tract Cancer+1
RECRUITINGPhase 1 / Phase 2NCT05797168

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and...

Sponsor: AstraZenecaEnrolling: 50620 locations
Ovarian CancerLung AdenocarcinomaEndometrial Cancer
RECRUITINGPhase 1 / Phase 2NCT07109219

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute...

Sponsor: AstraZenecaEnrolling: 8320 locations
B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITINGPhase 1 / Phase 2NCT07123454

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With...

This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in...

Sponsor: AstraZenecaEnrolling: 9120 locations
B-cell Non-Hodgkin Lymphoma
RECRUITINGPhase 1NCT07154901

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen...

This study is being conducted to investigate the PK, safety, and tolerability of opemalirsen in participants with renal impairment, compared to participants with normal renal...

Sponsor: AstraZenecaEnrolling: 502 locations
Renal Impairment
RECRUITINGPhase 3NCT06960577

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder...

The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected...

Sponsor: AstraZenecaEnrolling: 15020 locations
Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4
RECRUITINGPhase 2NCT06535607

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic...

eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.

Sponsor: AstraZenecaEnrolling: 25720 locations
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2
RECRUITINGNCT06951867

Tezspire Cardiac Events PASS

The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a...

Sponsor: AstraZenecaEnrolling: 166404 locations
Cardiovascular EventsMACE
RECRUITINGPhase 3NCT06307652

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and...

Sponsor: AstraZenecaEnrolling: 480020 locations
Heart Failure and Impaired Kidney Function
RECRUITINGPhase 3NCT06742723

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in...

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on...

Sponsor: AstraZenecaEnrolling: 500020 locations
Chronic Kidney Disease and Hypertension
RECRUITINGPhase 3NCT06015737

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute...

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus...

Sponsor: AstraZenecaEnrolling: 30220 locations
Cutaneous Lupus Erythematosus
RECRUITINGNCT07330245

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of...

Sponsor: AstraZenecaEnrolling: 21819 locations
Lupus Erythematosus, Systemic
RECRUITINGNCT07000110

Anifrolumab Malignancy and Serious Infections Study

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive...

Sponsor: AstraZenecaEnrolling: 31954 locations
Systemic Lupus Erythematosus
RECRUITINGNCT06795893

The Anifrolumab PRIM Program

Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program

Sponsor: AstraZenecaEnrolling: 2401 location
Systemic Lupus Erythematosus
RECRUITINGNCT06659029

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the...

Sponsor: AstraZenecaEnrolling: 4421 location
Systemic Lupus Erythematosus
RECRUITINGPhase 2NCT06681324

Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy

The purpose of this study is to evaluate safety, tolerability, and effect on mucosal repair of AZD7798 compared with placebo in participants with active ileal Crohn's disease and...

Sponsor: AstraZenecaEnrolling: 3020 locations
Crohn's Disease
RECRUITINGPhase 1NCT07295847

A Study of AZD0120 in Autoimmune Diseases

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult...

Sponsor: AstraZenecaEnrolling: 2718 locations
Systemic SclerosisIdiopathic Inflammatory MyopathiesRheumatoid Arthritis
RECRUITINGNCT07247279

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes...

Sponsor: AstraZenecaEnrolling: 4503 locations
Rare DiseasesGeneralized Myasthenia Gravis (gMG)
RECRUITINGNCT06909253

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Sponsor: AstraZenecaEnrolling: 5014 locations
Myasthenia Gravis, Generalized
RECRUITINGPhase 1NCT07316608

A Phase I, Open-label, Crossover Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of...

The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin...

Sponsor: AstraZenecaEnrolling: 442 locations
Healthy Participants
RECRUITINGNCT06948396

Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in...

This observational study aims to collect data in clinical practice on the clinical profile of patients treated with Tezepelumab from Q1 2024 to Q1 2025 according to the approved...

Sponsor: AstraZenecaEnrolling: 30020 locations
Asthma
RECRUITINGPhase 3NCT06307665

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years...

The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered...

Sponsor: AstraZenecaEnrolling: 44020 locations
Asthma
RECRUITINGNCT07399665

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within...

Sponsor: AstraZenecaEnrolling: 1106 locations
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Asthma
RECRUITINGNCT06427876

Fasenra Pediatric Japan Post-Marketing Study(PMS)

The purpose of the investigation is to confirm the followings under the post-marketing actual use of Fasenra® Subcutaneous Injection 30 mg / 10mg Syringe (hereinafter referred to...

Sponsor: AstraZenecaEnrolling: 4011 locations
Bronchial Asthma
RECRUITINGNCT07221981

Study of Patient With Frequent COPD Exacerbations

This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to...

Sponsor: AstraZenecaEnrolling: 20006 locations
Chronic Obstructive Pulmonary Disease (COPD)
RECRUITINGNCT07069829

Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease...

Sponsor: AstraZenecaEnrolling: 140012 locations
Chronic Obstructive Pulmonary Disease
RECRUITINGNCT07307781

Study of Patient With Frequent Exacerbations in Moscow

This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD...

Sponsor: AstraZenecaEnrolling: 5001 location
Chronic Obstructive Pulmonary Disease (COPD)
RECRUITINGNCT07245407

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic respiratory disease characterized by a clinical syndrome of chronic productive cough and recurrent respiratory infections in...

Sponsor: AstraZenecaEnrolling: 32020 locations
Non-cystic Fibrosis Bronchiectasis

Showing 30 of 34 trials.